# NRG/GOG Foundation

## Uterine Corpus Subcommittee

Gynecologic Oncology Group

Gynecologic Oncology Group

NRG ONCOLOGY

*Advancing Research. Improving Lives.™*

GOG Foundation/Partners

Gynecologic Oncology Group

# GOG0233/ACRIN 6671: Preoperative FDG-PET/CT to Detect Lymph Node Metastasis




Accrued: 384
Presented: ASCO 2011
Publication: Radiology (epub)

GOG Gynecologic Oncology Group

# Endometrial: Stage I/II Adjuvant




- 3/23/2009 – 2/4/2013: Completed
- Endorsed by RTOG
- 562 accrued, 9% CCOP
- Presented: SGO 2014
- Publication: in preparation

Gynecologic Oncology Group

# Endometrial: Stage III/IV




* first dose of Carboplatin will be at AUC of 5, in subsequent cycles the dose will be escalated to AUC 6, as described in Section 6.2

- 6/29/2009 – 7/28/2014: Completed
- Endorsed by RTOG
- 813/804 accrued
- Presentation: ASCO 2017

GOG Gynecologic Oncology Group

# Pelvic Recurrence

- 2/25/2008
- Endorsed by RTOG
- 115/154 accrued




Institution IMRT Credentialing is required when IMRT is to be used before registering any patient on this trial. A Knowledge Assessment for this study must be completed by the treating radiation oncologist before registering patients on this trial.

For patients with tumors involving the distal vagina and clinically negative groins, the bilateral inguino-femoral lymph node regions should be treated to 4500 cGy.

3-D conformal or IMRT boost is allowed for patients who are not candidates for brachytherapy.

# Leiomyosarcoma: Stage I




4 Jun 2012 opened
38/216 accrued
9 Sep 2016 closed

# LOW-RISK GESTATIONAL TROPHOBLASTIC NEOPLASIA




18 Jun 2012 opened
GCIG collaboration
57/384 accrued
20 Sep 2016 closed

GOG Gynecologic Oncology Group